urea has been researched along with Peripheral Arterial Diseases in 6 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Safety evaluations performed during 14- and 28-day visits which included in-clinic dosing and assessments at peak drug concentrations provided core data for the DMC review." | 2.76 | Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. ( Brass, EP; Connor, JT; Cooper, LT; Hiatt, WR; Lewis, RJ; Murphy, JR; Teerlink, JR, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Pietzsch, JB | 1 |
| Geisler, BP | 1 |
| Iken, AR | 1 |
| van Wijck, IPS | 1 |
| Holewijn, S | 1 |
| Reijnen, MMPJ | 1 |
| Chang, GH | 1 |
| Azar, DA | 1 |
| Lyle, C | 1 |
| Chitalia, VC | 1 |
| Shazly, T | 1 |
| Kolachalama, VB | 1 |
| Lewis, RJ | 1 |
| Connor, JT | 1 |
| Teerlink, JR | 1 |
| Murphy, JR | 1 |
| Cooper, LT | 2 |
| Hiatt, WR | 2 |
| Brass, EP | 2 |
| Morgan, RE | 1 |
| Yoshida, H | 2 |
| Itoh, S | 2 |
| Hara, T | 1 |
| Sasaki, Y | 2 |
| Kondo, S | 2 |
| Nakagawa, T | 1 |
| Asanuma, A | 1 |
| Tanabe, S | 2 |
| Suzuki, H | 1 |
| Inoue, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00783081] | Phase 2 | 387 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for urea and Peripheral Arterial Diseases
| Article | Year |
|---|---|
Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication.
Topics: Ankle Brachial Index; Decision Support Techniques; Dose-Response Relationship, Drug; Double-Blind Me | 2011 |
A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Chi-Square Distribution; Cilostazol; Dose-Resp | 2012 |
4 other studies available for urea and Peripheral Arterial Diseases
| Article | Year |
|---|---|
Cost-Effectiveness of Urea Excipient-Based Drug-Coated Balloons for Chronic Limb-Threatening Ischemia from Femoropopliteal Disease in the Netherlands and Germany.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Chronic Limb-Threatening Ischemia; Coated Materials, Bi | 2022 |
Intrinsic coating morphology modulates acute drug transfer in drug-coated balloon therapy.
Topics: Angioplasty, Balloon; Cell Death; Cell Survival; Cells, Cultured; Coated Materials, Biocompatible; E | 2019 |
A phosphodiesterase 3 inhibitor, K-134, improves hindlimb skeletal muscle circulation in rat models of peripheral arterial disease.
Topics: Administration, Oral; Animals; Blood Flow Velocity; Disease Models, Animal; Dose-Response Relationsh | 2012 |
K-134, a phosphodiesterase 3 inhibitor, improves gait disturbance and hindlimb blood flow impairment in rat peripheral artery disease models.
Topics: Animals; Disease Models, Animal; Hindlimb; Lameness, Animal; Male; Peripheral Arterial Disease; Phos | 2012 |